Genmab — Maj 2018
-
Det er cd3-armen i et bispecifikt antistof. Denne arm binder til et antigen på overfladen af T-cellerne. Herved opstår en risiko for "over-aktivering" af T-cellerne - CRS-syndrom. Eller cytokin storm. Det samme problem som ses ved car-t. Ved at "dæmpe" cd3-armen mindsker man risikoen for denne overaktivering.
-
Mon dette er en duobody http://www.freepatentsonline.com/y2017/0121420.html
-

-
Husk nu, at man som CEO i et børsnoteret selskab skal være varsom med offentlige kommentarer.
-
Tror faktisk, at de store partnerne er meget nidkære omkring kommunikationen omkring det de deltager i sammen med Genmab.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
